Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 13

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 13
---
 expenses. Our management will have broad discretion as to the application of the net proceeds
from this offering and could use them for purposes other than those contemplated at the time of this offering, as described below in the
section entitled “Use of Proceeds,” or in ways that do not necessarily improve our operating results or enhance the
value of our common shares. The precise amount and timing of the application of these proceeds will depend upon a number of factors, such
as the timing and progress of our research and development efforts, our funding requirements and the availability and costs of other funds.
As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from
this offering. Depending on the outcome of our efforts and other unforeseen events, our plans and priorities may change and we may apply
the net proceeds of this offering in different manners than we currently anticipate. Our shareholders may not agree with the manner in
which our management chooses to allocate and spend the net proceeds. Our failure to use these funds effectively could have a material
adverse effect on our business and could cause the price of our securities to decline.

**It is not possible to predict the aggregate
proceeds resulting from sales made under the Sales Agreement.**

Subject to certain limitations in the
Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Sales Agent at any time
throughout the term of the Sales Agreement. The number of shares that are sold through the Sales Agent after delivering a placement notice
will fluctuate based on a number of factors, including the market price of our common shares during the sales period, the limits we set
with the Sales Agent in any applicable placement notice, and the demand for our common shares during the sales period. Because the price
per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the aggregate proceeds to
be raised in connection with those sales.

| S-7 |

**The common shares offered hereby will be sold
in “at the market offerings,” and investors who buy shares at different times will likely pay different prices.**

Investors who purchase shares in this
offering at different times will likely pay different prices, and so may experience different levels of dilution and different outcomes
in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and number of shares sold
in this offering. In addition, subject to